Frontiers in Cardiovascular Medicine (Oct 2022)

Incidence, recurrence and management of electrical storm in Brugada syndrome

  • Ibrahim El-Battrawy,
  • Ibrahim El-Battrawy,
  • Ibrahim El-Battrawy,
  • Gretje Roterberg,
  • Jacqueline Kowitz,
  • Assem Aweimer,
  • Siegfried Lang,
  • Siegfried Lang,
  • Andreas Mügge,
  • Xiaobo Zhou,
  • Xiaobo Zhou,
  • Ibrahim Akin,
  • Ibrahim Akin

DOI
https://doi.org/10.3389/fcvm.2022.981715
Journal volume & issue
Vol. 9

Abstract

Read online

BackgroundBrugada syndrome (BrS) is associated with ventricular tachyarrhythmias. However, the presence of electrical strom (ES) and its management still debated.ObjectivesWe present the outcome and management of 44 BrS patients suffering from ES.MethodsA systematic literature review and pooled analysis Through database review including PubMed, Web of Science, Cochrane Libary and Cinahl studies were analyzed. Evidence from 7 reports of 808 BrS patients was identified.ResultsThe mean age of patients suffering from ES was 34 ± 9.5 months (94.7% males, 65.8% spontaneous BrS type I). Using electrophysiological study ventricular tachycardia/ventricular fibrillation were inducible in 12/23 (52.2%). Recurrence of ES was documented in 6.1%. Death from ES was 8.2% after a follow-up of 83.5 ± 53.4. In up to 27 ES resolved without treatment. External shock was required in 35.6%, internal ICD shock in 13.3%, Overdrive pacing, left cardiac sympathetic block and atropin in 2.2%. Short-term antiarrhythmic management was as the following: Isopreterenol or Isopreterenol in combination with quinidine 35.5%, orciprenaline in 2.2%, quinidine 2.2%, disopyramide 2.2% or denopamide 2.2%. However, lidocaine, magensium sulfate, mexiletine and propanolol failed to control ES.ConclusionAlthough ES is rare in BrS, this entity challenges physicians. Despite its high mortality rate, spontaneous termination is possible. Short-term management using Isoproterenol and/or quinidine might be safe. Prospective studies on management of ES are warranted.

Keywords